Global Blood Therapeutics, Inc. (GBT) to Release Earnings on Tuesday
Global Blood Therapeutics, Inc. (NASDAQ:GBT) will post its quarterly earnings results after the market closes on Tuesday, November 7th. Analysts expect Global Blood Therapeutics to post earnings of ($0.62) per share for the quarter.
Global Blood Therapeutics (NASDAQ:GBT) last released its quarterly earnings results on Monday, August 7th. The company reported ($0.55) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.61) by $0.06. During the same period last year, the firm earned ($0.58) EPS. On average, analysts expect Global Blood Therapeutics to post $-2.42 EPS for the current fiscal year and $-2.83 EPS for the next fiscal year.
Shares of Global Blood Therapeutics, Inc. (GBT) opened at 38.65 on Tuesday. The firm’s market capitalization is $1.69 billion. Global Blood Therapeutics, Inc. has a 1-year low of $13.35 and a 1-year high of $41.15. The stock has a 50 day moving average price of $30.87 and a 200 day moving average price of $29.28.
TRADEMARK VIOLATION NOTICE: “Global Blood Therapeutics, Inc. (GBT) to Release Earnings on Tuesday” was first published by American Banking News and is owned by of American Banking News. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of United States & international trademark & copyright laws. The original version of this piece can be accessed at https://www.americanbankingnews.com/2017/10/31/global-blood-therapeutics-inc-gbt-to-release-earnings-on-tuesday.html.
GBT has been the subject of several recent analyst reports. Cowen and Company restated an “outperform” rating and set a $83.00 target price on shares of Global Blood Therapeutics in a research note on Monday, August 14th. Wedbush restated an “ourperform” rating and set a $73.00 target price on shares of Global Blood Therapeutics in a research note on Monday, September 18th. Morgan Stanley restated an “overweight” rating on shares of Global Blood Therapeutics in a research note on Tuesday, July 11th. BidaskClub upgraded Global Blood Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, August 17th. Finally, Zacks Investment Research cut Global Blood Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday, October 16th. Three investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $54.08.
In related news, insider Jung Choi sold 3,000 shares of the stock in a transaction on Thursday, August 31st. The stock was sold at an average price of $30.00, for a total value of $90,000.00. Following the completion of the sale, the insider now directly owns 141,655 shares in the company, valued at $4,249,650. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Charles J. Homcy sold 70,000 shares of the stock in a transaction on Friday, October 27th. The shares were sold at an average price of $33.97, for a total value of $2,377,900.00. Following the completion of the sale, the director now owns 83,328 shares of the company’s stock, valued at $2,830,652.16. The disclosure for this sale can be found here. Insiders have sold 79,000 shares of company stock valued at $2,655,850 over the last quarter. Company insiders own 5.30% of the company’s stock.
About Global Blood Therapeutics
Global Blood Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD).
Receive News & Ratings for Global Blood Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.